NCT00753454View on ClinicalTrials.gov

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

PHASE3CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Certolizumab pegol

Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).

Trial Locations (40)

Unknown

Huntsville

Paradise Valley

Tucson

Little Rock

Huntington Beach

La Jolla

Los Angeles

Palm Desert

San Diego

Aventura

Clearwater

Gainesville

Jacksonville

Jupiter

Melbourne

Sarasota

Morton Grove

Vernon Hills

Lexington

Haverhill

Worcester

Rochester

Lincoln

Las Vegas

Reno

Albany

Mineola

Syracuse

Charlotte

Monroe

Wilmington

Norman

Duncansville

Dallas

San Antonio

Tyler

Winnipeg

St. John's

St. Catharines

Toronto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY

NCT00753454 - Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter